Zhang et al. (44) found that MCH levels before treatment could serve as a predictive marker linked to disease-free survival (DFS) in breast cancer, as patients in the higher MCH group exhibited shorter DFS times than those in the lower MCH group. This evidence concerns the gene PMCH and breast cancer.